NCT06917040View on ClinicalTrials.gov

Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria

PHASE3CompletedINTERVENTIONAL
Enrollment

18,404

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Leishmaniasis, CutaneousVector Borne Diseases
Interventions
DEVICE

Spatial repellant emanator

Spatial emanator with an active ingredient Transfluthrin (C15H12Cl2F4O2, 110mg, EPA registered number 432-1588).

Trial Locations (1)

Unknown

The MENTOR Initiative, North East Syria, Ar-Raqqa

All Listed Sponsors
collaborator

University of Nevada, Las Vegas

OTHER

collaborator

Hacettepe University

OTHER

lead

The Mentor Initiative

OTHER

NCT06917040 - Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria | Biotech Hunter | Biotech Hunter